15-PGDH

Glycyrrhetinic acid inhibits the enzymes (15-hydroxyprostaglandin dehydrogenase and delta-13-prostaglandin) that metabolize the prostaglandins PGE-2 and PGF-2α to their respective 15-keto-13,14-dihydro metabolites which are inactive.

SW033291 is a small-molecule inhibitor of 15-PGDH (Ki=0.1 nM) that increases prostaglandin PGE2 levels in bone marrow and other tissues.

MF-DH-300 is a selective inhibitor of 15-PGDH, a key enzyme in the degradation of prostaglandins. By inhibiting this enzyme, MF-DH-300 enhances prostaglandin levels, which may have therapeutic implications in muscle disorders, such as spinal muscular atrophy (SMA). This compound is valuable for research focused on understanding the role of prostaglandins in muscle-related pathologies and developing potential interventions.

ML148 is a potent and selective inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), exhibiting an IC50 of 56 nM. This compound is particularly valuable for the investigation of prostaglandin signaling pathways, which play critical roles in inflammation, pain, and various physiological processes. ML148’s specificity and inhibitory capacity make it a crucial tool for exploring the modulation of prostaglandin metabolism in various biological contexts.

15-PGDH-IN-1 is a potent inhibitor of the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) with an IC50 value of 3 nM against recombinant human 15-PGDH. This compound is orally active and is valuable for investigating the roles of 15-PGDH in tissue repair and regeneration processes. Its inhibitory action may facilitate research into therapeutic strategies targeting inflammation and cellular regeneration.

HW201877 is an effective and orally active inhibitor of 15-prostaglandin dehydrogenase (15-PGDH) with an IC50 value of 3.6 nM. This compound significantly increases PGE2 levels in A549 cells and has demonstrated notable efficacy in preclinical models of tissue injury and fibrosis. HW201877 is suitable for investigating inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF), and Crohn’s disease (CD).

15-PGDH-IN-4 is a potent inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), exhibiting an IC50 value of 1.2 nM against human 15-PGDH. This reagent is valuable for research into immune cell function and tissue regeneration, enabling the exploration of metabolic pathways and inflammatory processes. Its ability to modulate 15-PGDH activity makes it a critical tool for studies aimed at understanding and manipulating prostaglandin signaling.

(R)-SW033291 is a potent and high-affinity inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). By inhibiting this enzyme, (R)-SW033291 significantly increases levels of prostaglandin E2 (PGE2) in bone marrow and other tissues. This compound has potential applications in research focused on tissue regeneration and the modulation of inflammatory responses associated with prostaglandin signaling.

MF-PGDH-008 is a selective inhibitor of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH). This compound plays a crucial role in modulating prostaglandin levels, offering significant potential in research focused on inflammation and cancer biology. Its ability to inhibit 15-PGDH makes it valuable for exploring therapeutic strategies aimed at enhancing prostaglandin signaling in various biomedical studies.

15-PGDH-IN-3 is a selective competitive inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). This compound plays a critical role in regulating prostaglandin levels and can be utilized to study the modulation of inflammatory responses and cancer progression. Its inhibition of 15-PGDH may have implications in various research applications, including pain management and the investigation of therapeutic targets in oncology.

CAY10397 is a selective and orally bioavailable inhibitor of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). It effectively inhibits the production of endogenous metabolites dependent on 15-PGDH, and it has been shown to block selenium-dependent protective mechanisms in inflammation. CAY10397 is primarily utilized in research related to colitis and other inflammatory conditions, providing insights into the role of 15-PGDH in disease pathology.

15-epi-PGE1 is a stereoisomer of Prostaglandin E1 that functions as a non-competitive inhibitor of human placental 15-Hydroxyprostaglandin dehydrogenase (15-PGDH). With an IC50 value of 170 μM, this compound exhibits inhibitory activity that can be utilized in studies of prostaglandin metabolism. Research applications may include investigations into the roles of prostaglandins in various physiological and pathological processes.

15-PGDH-IN-2 is a potent inhibitor of 15-PGDH, displaying an IC50 value of 0.274 nM. This compound is valuable for researching biological processes such as hair loss, bone formation, gastric ulcer healing, and dermal wound healing. Its ability to modulate 15-PGDH activity makes it a useful tool in studying pathways associated with these conditions.